-
The intellectual property landscape in the field of plasmid-based gene therapy.
Technology Venturing, Valentis, Inc, The Woodlands, TX 77381, USA. Fonsm@valentis.com
As plasmid-based gene therapy products progress through clinical trials commercial entities begin to focus on the intellectual property associated with the methods and specific compositions used in these therapies. As the number of patents covering gene therapy components and methods increases it becomes increasingly difficult for a single entity to collect all of the necessary rights to be able to offer gene therapy products to consumers. The present report briefly describes the relevance of patents to product commercialization and describes certain key patents that may affect the ultimate commercialization potential of this new and exciting technology.
PMID: 10758911 [PubMed - indexed for MEDLINE]
-
Related articles
-
ReviewINGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D. 2007; 8(3):176-87.
[Drugs R D. 2007]
-
ReviewPlasmid DNA manufacturing technology.
Recent Pat Biotechnol. 2007; 1(2):151-66.
[Recent Pat Biotechnol. 2007]
-
ReviewINGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs. 2003; 17(3):216-22.
[BioDrugs. 2003]
-
ReviewIntellectual property: patents and transfer agreements preceding clinical trials and commercialization.
Retina. 2005 Dec; 25(8 Suppl):S91-S94.
[Retina. 2005]
-
ReviewEfaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D. 2005; 6(3):178-85.
[Drugs R D. 2005]
- » See reviews... | » See all...